Evidence map›Paper›PMID 30386648›Full record

ArticleCentral European journal of urology2018

Low molecular weight proteins and enzymes in the urine of patients with bladder cancer - a pilot study.

Zofia Marchewka, Beata Szymańska, Janusz Dembowski, Anna Długosz, Agnieszka Piwowar

Abstract read
In one paragraph

Article in Central European journal of urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Automated DNA, RNA, and Protein Extraction from Urine for Biobanking.Journal of biomolecular techniques : JBT · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zofia MarchewkaDepartment of Toxicology, Laboratory of Environmental Nephrotoxicity Markers, Faculty of Pharmacy, Wrocław Medical University, Wrocław, Poland.
Beata SzymańskaDepartment of Toxicology, Laboratory of Environmental Nephrotoxicity Markers, Faculty of Pharmacy, Wrocław Medical University, Wrocław, Poland.
Janusz DembowskiClinic of Urology and Urological Oncology, Faculty of Postgraduate Medical Training, Wrocław Medical University, Wrocław, Poland.
Anna DługoszDepartment of Toxicology, Faculty of Pharmacy, Wrocław Medical University, Wrocław, Poland.
Agnieszka PiwowarDepartment of Toxicology, Faculty of Pharmacy, Wrocław Medical University, Wrocław, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionA steady increase in cases of bladder cancer (BC) has been observed. Detection of unfavorable changes, especially in the early stages of disease, is crucial to medical procedure. There is still a need to search for new, non-invasive biomarkers of BC. The aim of this study was to estimate the levels of selected low molecular weight proteins (LMWP) and enzymes in the urine of patients at different BC stages and grades. MATERIAL AND

methodsUrine samples from 46 patients with BC and 16 healthy controls were examined. We measured levels of LMWP such as: retinol-binding protein (RBP), β2 -microglobulin (β2M), enzymes: N-acetyl-β-D-glucosaminidase (NAG), isoform (NAG-B) and also neutrophil gelatinase-associated lipocalin (NGAL).

resultsThe levels of all examined parameters differed between patients and healthy subjects. Levels of NAG (p = 0.031), NAG-B (p = 0.023) and NGAL (p = 0.008), and total protein (p = 0.007) concentrations, were significantly higher in the BC patients than in the control group. Among the examined parameters, positive significant correlations were observed only between urinary NGAL concentration and tumor stages and grades. The highest percentages of changes in NGAL concentration were observed in tumor in situ (TIS) and G3grade patients.

conclusionsOur study showed that urinary NGAL concentrations, as well as NAG and NAG-B activity, could be helpful noninvasive parameters for the diagnosis of BC. The most promising seems to be NGAL determination, but further study is needed on a larger group of participants in order to confirm this observation.

Indexed as

bladder cancerlow molecular weight proteinsNAGNGALurine

Identifiers

PMID30386648
PMCPMC6202615

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.